Aspartic Acid: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 15, 2026🚩 Report this page

Aspartic Acid

Active ingredient

GB MHRA

Drug class: -
Availability: See label
Markets covered: 1
Products on record: 1

Overview

Aspartic Acid is an active pharmaceutical ingredient. The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	1	May 15, 2026

GBUnited Kingdom· MHRA

1 product

Uses

GBOfficial regulatory label· revised May 15, 2026[1]

NumetaG19%E is indicated for parenteral nutrition in children older than 2 years and adolescents 16-18 years old when oral or enteral nutrition is not possible, insufficient or contraindicated.

How to take

Sources & citations

[1]MHRA (UK) · PL001160649 · revised May 15, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Posology The dosage depends on energy expenditure, the patient’s weight, age, clinical status, and on the ability to metabolize the constituents of Numeta, as well as on additional energy or proteins given orally/enterally. Total electrolyte and macronutrient composition is dependent on the number of activated chambers (See section 2).
The maximum daily dose should not be exceeded. Due to the static composition of the multi-chamber bag, the ability to simultaneously meet all nutrient needs of the patient may not be possible. Clinical situations may exist where patients require amounts of nutrients varying from the composition of the static bag.
The maximal recommended hourly rate of infusion and volume per day depend on the constituent. The first of these limits to be reached sets the maximum daily dose. 6. 6). 2 micron filter is recommended for administration of Numeta G19%E.
Due to its high osmolarity, undiluted Numeta G19%E can only be administered through a central vein. However, sufficient dilution of Numeta G19%E with water for injection lowers the osmolarity and allows peripheral infusion. The table below indicates the minimum volume of water for injection to be added to the activated bag in order to achieve the target osmolarity for peripheral administration.
It should be noted that any other addition made to the activated bag will modify the final osmolarity. Target Osmolarity (mOsm/L) Minimum addition of water for injection to achieve target osmolarity (mL) < 900 690 < 850 800 Numeta G19%Ea after 3- in-1 activation < 800 920 aThe dilution of Numeta G19%E 2-in-1 admixture for peripheral administration for children and adolescents up to 18 years is not appropriate because the volume of water which would be required to be added exceeds bag capacity and may exceed patients’ daily fluid requirements.
The flow rate should be increased gradually during the first hour. Upon discontinuation of Numeta G19%E, the flow rate should be decreased gradually during the last hour. 9. The same bag should not be activated, hung and infused longer than 24 hours.
Cyclic infusions should be managed according to the patient’s metabolic tolerance. Treatment with parenteral nutrition may be continued for as long as is required by the patient’s clinical conditions. 6. 6.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised May 15, 2026[1]

1 Adverse Reactions from Clinical Trials and Post-marketing experience The safety and administration of Numeta was assessed in a single phase III study. One hundred and fifty nine (159) paediatric patients were included in the study and received Numeta.
The pooled data from clinical trials and the postmarketing experience indicate the following adverse drug reactions (ADRs) related to Numeta: Clinical Trial and Post-marketing experience Adverse Reactions System Organ Class (SOC) Preferred MedDRA Term Frequencyb METABOLISM AND NUTRITION DISORDERS Hypophosphataemiaa Hyperglycaemiaa Hypercalcaemiaa Hypertriglyceridaemiaa Hyperlipidaemia Hyponatraemiaa Common Common Common Common Uncommon Common HEPATOBILIARY DISORDERS Cholestasis Uncommon Skin necrosis c Not knownSKIN AND SUBCUTANEOUS TISSUE DISORDERS Soft tissue injury c Not known GENERAL DISORDERS AND ADMINISTRATION SITE CONDITION Extravasation c Not known a Blood samples drawn during the infusion (without fasting conditions).
b Frequency is based upon the following categories: Very Common (≥1/10); Common (≥1/100 - <1/10), Uncommon (≥1/1,000 - <1/100), Rare (≥1/10,000 - <1/1,000), Very Rare (<1/10,000), Not known (cannot be estimated based on available data).
g. 9); however the signs and symptoms of this syndrome may also occur when the product is administered according to instructions. The reduced or limited ability to metabolize the lipids contained in Numeta G19%E accompanied by prolonged plasma clearance may result in a “fat overload syndrome”.
g. coma). 4). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
uk/yellowcard

GBOfficial regulatory label· Warnings and precautions· revised May 15, 2026[1]

The infusion must be stopped immediately if any signs or symptoms of an allergic reaction (such as fever, sweating, shivering, headache, skin rashes, or dyspnea) develop. Numeta G19%E contains glucose produced from cornstarch. Therefore, Numeta G19%E should be used with caution in patients with known allergy to corn or corn products.
In patients of any age (including adults), ceftriaxone must not be mixed or administered simultaneously with any intravenous calcium-containing solutions, including Numeta G19%E, even via different infusion lines or at different infusion sites because of the risk of precipitation of ceftriaxone-calcium salt.
However, in patients older than 28 days of age ceftriaxone and calcium-containing solutions may be administered sequentially one after another if infusion lines at different sites are used or if the infusion lines are replaced or thoroughly flushed between infusions with physiological salt-solution to avoid precipitation.
Pulmonary vascular precipitates causing pulmonary vascular embolism and respiratory distress have been reported in patients receiving parenteral nutrition. In some cases, fatal outcomes have occurred. 2). Suspected precipitate formation in the blood stream have also been reported.
In addition to inspection of the solution, the infusion set and catheter should also periodically be checked for precipitates. If signs of respiratory distress occur, the infusion should be stopped and medical evaluation initiated. 6.
Infection and sepsis may occur as a result of the use of intravenous catheters to administer parenteral formulations, or poor maintenance of catheters. Immunosuppressive effects of illness, or drugs, may promote infection and sepsis.
Careful symptomatic and laboratory monitoring for fever/chills, leukocytosis, technical complications with the access device, and hyperglycaemia can help recognize early infections. Patients who require parenteral nutrition are often predisposed to infectious complications due to malnutrition and/or their underlying disease state.
The occurrence of septic complications can be decreased with heightened emphasis on aseptic technique in catheter placement, maintenance, as well as aseptic technique in nutritional formula preparation. Fat overload syndrome has been reported with other parenteral nutrition products.

This is not medical advice. Consult a qualified healthcare professional.